

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV306636646US  
Express Mail Label Number

August 18, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/028,374

FILED: DECEMBER 20, 2001

FOR: NOVEL HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN  
EXPRESSED PREDOMINANTLY IN BONE MARROW, HLRRBM1

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:


Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: August 18, 2003

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



RECEIVED  
AUG 21 2003  
CASE DOCKET  
TECH CENTER 1600/2900

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV306636646US  
Express Mail Label Number

August 1, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/028,374

FILED: DECEMBER 20, 2001

FOR: NOVEL HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN  
EXPRESSED PREDOMINANTLY IN BONE MARROW, HLRRBM1

MAIL STOP: DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

08/20/2003 50ENB001 00000086 193800 10020374  
C. FC1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: August 18, 2003

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

D0067 NP

APPLICATION NO.

10/028,374

APPLICANT

FEDER ET AL.


FILING DATE

DECEMBER 20, 2001

Group

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO0240668	5/23/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO02061049	8/8/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	NCBI Accession No. gi:21955154, Wang, et al., April 18, 2003
	AS	NCBI Accession No. gi:21711827, Williams, et al., May 21, 2003
	AT	NCBI Accession No. gi:21711825, Williams, et al., May 21, 2003

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

ATTY. DOCKET NO.  
D0067 NP  
APPLICATION NO.  
10/028,374  
APPLICANT  
FEDER ET AL.  
FILING DATE  
DECEMBER 20, 2001

**RECEIVED**

AUG 21 2003

TECH CENTER 1600/2900



(See several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	NCBI Accession No. gi:21711823, Williams, et al., 5/21/03
2AB	NCBI Accession No. gi:21711821, Williams, et al., 5/21/03
2AC	NCBI Accession No. gi:24212103, Wang, et al., 9/15/03
2AD	NCBI Accession No. gi:21449785, Reed, et al., 6/14/02
2AE	NCBI Accession No. gi:20380400, Strausberg, et al., 4/22/03
2AF	NCBI Accession No. gi:28436378, Martinon, et al., 2/20/03
2AG	Wang, et al. (2002) J. of Biological Chemistry 277 (33):29874-29880
2AH	Tschopp, et al. (2003) Nature Reviews Molecular Cell Biology 4:95-104
AI	
AJ	
AK	
AL	
AM	
AN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.